Bianca Lattanzi

Bianca Lattanzi

Auto-generated profile, based on publicly available information

Bianca Lattanzi

Pediatric Unit, Department of Mother and Child Health, Salesi Children's Hospital , Ancona , Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
GFGiovanni Filocamo
Giovanni Filocamo
ACAlessandro Consolaro
Alessandro Consolaro
BSBenedetta Schiappapietra
Benedetta Schiappapietra
SDSara Dalprà
Sara Dalprà
BLBianca Lattanzi
Bianca Lattanzi
Angelo RavelliAngelo Ravelli
Angelo Ravelli
Objective.: To develop and test a new multidimensional questionnaire for assessment of children with juvenile idiopathic arthritis (JIA) in standard clinical care.Methods.: The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) includes 15 parent or patient-centered measures or items that assess well-being, pain, functional status, health-related quality of life, morning stiffness, disease activity, disease status and course, joint disease, extraarticular symptoms, side effects of medications, therapeutic compliance, and satisfaction with illness outcome. The JAMAR is proposed for use as both a proxy-report and a patient self-report, with the suggested age range of 7–18 years for use as a self-report. From March 2007 to September 2009, the questionnaire was completed by the parents of 618 children with JIA in 1814 visits and by 332 children in 749 visits.Results.: The JAMAR was found to be feasible and to possess face and content validity. All parents and children reported that the questionnaire was simple and easy to understand. Completion and scoring appeared to be quick, requiring < 15 minutes. There were very few missing data. Parents’ proxy-reported and children’s self-reported data were remarkably concordant. The JAMAR provided thorough information for the study patients about recent medical history and current health status. It performed similarly across different children’s ages and characterized the level of disease activity and disability well.Conclusion.: The development of the JAMAR introduces a new approach in pediatric rheumatology practice. This new questionnaire may help enhance the quality of care of children with JIA.

8 October 2010 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
Angelo RavelliAngelo Ravelli
Angelo Ravelli
GVGiulia C. Varnier
Giulia C. Varnier
SOSheila Oliveira
Sheila Oliveira
ECEsteban Castell
Esteban Castell
OAOlga Arguedas
Olga Arguedas
AMAlberto Martini
Alberto Martini
Objective: We undertook this study to test the hypothesis that in the International League of Associations for Rheumatology (ILAR) classification of juvenile idiopathic arthritis (JIA), patients with similar characteristics can be classified into different categories. We sought to investigate whether antinuclear antibody (ANA)–positive patients having disease in the ILAR categories of oligoarthritis, rheumatoid factor–negative polyarthritis, psoriatic arthritis, and undifferentiated arthritis share homogeneous features and to compare these features with those of ANA‐negative patients having the same categories of disease.Methods: We identified JIA patients who had been followed up during a 22‐year period. ANA positivity was defined as ≥2 positive results at a titer of ≥1:160. Demographic and clinical features were recorded retrospectively and compared between ANA‐positive and ANA‐negative patients.Results: Of a total of 971 patients, 711 were ANA positive, 149 were ANA negative, and 111 had an indeterminate ANA status. Patients with indeterminate ANA status were excluded. ANA‐positive patients in the different ILAR categories were similar in terms of age at disease presentation, female‐to‐male ratio, and frequency of asymmetric arthritis and iridocyclitis. Compared with ANA‐positive patients, the ANA‐negative group was older at disease presentation and had a lower prevalence of females, a lower frequency of iridocyclitis and asymmetric arthritis, a greater number of affected joints over time, and a different pattern of arthritis. The close relationship between the presence of ANAs and younger age at disease presentation, female predominance, asymmetric arthritis, development of iridocyclitis, lower number of affected joints over time, and lack of hip involvement was also confirmed by multivariate and multiple correspondence analysis.Conclusion: Our findings substantiate the hypothesis that ANA‐positive patients classified into different JIA categories by current ILAR criteria constitute a homogeneous patient population.

15 June 2010 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
GFGiovanni Filocamo
Giovanni Filocamo
SDSergio Davì
Sergio Davì
APAngela Pistorio
Angela Pistorio
MBMarta Bertamino
Marta Bertamino
NRNicolino Ruperto
Nicolino Ruperto
Angelo RavelliAngelo Ravelli
Angelo Ravelli
Objective.: To evaluate the measurement properties of 21-numbered circle visual analog scales (VAS) and traditional 10-cm horizontal line VAS for physician and parent subjective ratings in children with juvenile idiopathic arthritis (JIA).Methods.: We studied 2 patient samples in whom physician global rating of overall disease activity, parent global rating of the child’s overall well-being, and parent rating of intensity of child’s pain were performed using traditional 10-cm horizontal line VAS (n = 397) or 21-numbered circle VAS (n = 471). The measurement performances of the 2 VAS formats were examined by assessing construct validity, score distribution, responsiveness to change over time, and minimal clinically important difference (MCID).Results.: Most Spearman correlations with other JIA outcome measures yielded by 21-numbered circle VAS were greater than those obtained with 10-cm horizontal line VAS, revealing that the circle VAS format has better construct validity. Ceiling effects (i.e., score = 0) for physician and parent global ratings were 43.7% and 32.9%, respectively, on 21-numbered circle VAS, and 31.6% and 35.3%, respectively, on 10-cm horizontal line VAS. Responsiveness of 21-numbered circle VAS was good (standardized response mean > 0.8) or moderate (standardized response mean > 0.6) among patients classified as improved or worsened, respectively, by the physician or the parent. Overall, MCID values for 21-numbered circle VAS tended to be greater for worsening than for improvement.Conclusion.: The 21-numbered circle VAS are a suitable alternative to the 10-cm horizontal line VAS and may facilitate incorporation of physician and parent subjective ratings in standard clinical practice.


15 April 2015 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
FMFrancesca Minoia
Francesca Minoia
SDSergio Davì
Sergio Davì
AHAnnaCarin Horne
AnnaCarin Horne
FBFrancesca Bovis
Francesca Bovis
EDErkan Demirkaya
Erkan Demirkaya
Angelo RavelliAngelo Ravelli
Angelo Ravelli
Objective.: To seek insights into the heterogeneity of macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA) through the analysis of a large patient sample collected in a multinational survey.Methods.: International pediatric rheumatologists and hemato-oncologists entered their patient data, collected retrospectively, in a Web-based database. The demographic, clinical, laboratory, histopathologic, therapeutic, and outcome data were analyzed in relation to (1) geographic location of caring hospital, (2) subspecialty of attending physician, (3) demonstration of hemophagocytosis, and (4) severity of clinical course.Results.: A total of 362 patients were included by 95 investigators from 33 countries. Demographic, clinical, laboratory, and histopathologic features were comparable among patients seen in diverse geographic areas or by different pediatric specialists. Patients seen in North America were given biologics more frequently. Patients entered by pediatric hemato-oncologists were treated more commonly with biologics and etoposide, whereas patients seen by pediatric rheumatologists more frequently received cyclosporine. Patients with demonstration of hemophagocytosis had shorter duration of sJIA at MAS onset, higher prevalence of hepatosplenomegaly, lower levels of platelets and fibrinogen, and were more frequently administered cyclosporine, intravenous immunoglobulin (IVIG), and etoposide. Patients with severe course were older, had longer duration of sJIA at MAS onset, had more full-blown clinical picture, and were more commonly given cyclosporine, IVIG, and etoposide.Conclusion.: The clinical spectrum of MAS is comparable across patients seen in different geographic settings or by diverse pediatric subspecialists. There was a disparity in the therapeutic choices among physicians that underscores the need to establish uniform therapeutic protocols.

1 March 2017 in The Lancet
Verified
Journal Article
Closed access
Angelo RavelliAngelo Ravelli
Angelo Ravelli
SDSergio Davì
Sergio Davì
GBGiulia Bracciolini
Giulia Bracciolini
APAngela Pistorio
Angela Pistorio
ACAlessandro Consolaro
Alessandro Consolaro
AMAlberto Martini
Alberto Martini